Eledon Pharmaceuticals, Inc. (DE:2TK)
NASDAQ:2TK
2TK Stock Chart & Stats
€3.36
-€0.10(-2.29%)
At close: 4:00 PM EST
€3.36
-€0.10(-2.29%)
Day’s Range― - ―
52-Week Range€1.17 - €3.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€228.35M
Enterprise Value€222.81M
Total Cash (Recent Filing)€111.09M
Total Debt (Recent Filing)€555.00K
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding77,187,820
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.94Price Target Upside106.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance Sheet FlexibilityVery low debt materially reduces near-term bankruptcy and interest-rate risk, giving management flexibility to fund clinical programs through equity or partnerships. This structural strength helps preserve runway options and strategic choices across 2–6 months of development.
Focused Pipeline With Lead AssetA clearly focused lead program (tegoprubart) targeting a defined immunology pathway gives the company a coherent clinical strategy and clearer regulatory pathway. Concentrated R&D efforts can improve execution focus and make partnership or out‑licensing discussions more straightforward.
External Collaboration / Clinical InterestThird‑party development interest in combining another company’s cell therapy with tegoprubart signals external validation of mechanism and creates potential co-development pathways. Such collaborations can expand indications, share costs, and structurally de‑risk the program over time.
Bears Say
Pre-revenue With Large Ongoing LossesA sustained pre‑revenue profile with large net and operating losses means the firm must convert clinical results into commercial value to reach self-sufficiency. Continued negative earnings increase execution risk and require successful trials or deals to avoid permanent value erosion.
High Cash Burn / Negative Operating Cash FlowMaterial negative operating and free cash flow implies ongoing financing needs to sustain trials. Persistent cash burn constrains the ability to expand programs, forces prioritization between studies, and raises the probability of dilutive financings or restricted operational pacing over the medium term.
Reliance On Equity Financing / Dilution RiskDependence on equity raises as the chief funding source risks shareholder dilution and can erode equity value if raises recur. Without partnered revenue streams or products, recurring funding needs make long‑term planning and sustained R&D investment contingent on markets and investor appetite.
Eledon Pharmaceuticals News
2TK FAQ
What was Eledon Pharmaceuticals, Inc.’s price range in the past 12 months?
Eledon Pharmaceuticals, Inc. lowest stock price was €1.17 and its highest was €3.70 in the past 12 months.
What is Eledon Pharmaceuticals, Inc.’s market cap?
Eledon Pharmaceuticals, Inc.’s market cap is €228.35M.
When is Eledon Pharmaceuticals, Inc.’s upcoming earnings report date?
Eledon Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 58 days.
How were Eledon Pharmaceuticals, Inc.’s earnings last quarter?
Eledon Pharmaceuticals, Inc. released its earnings results on May 13, 2026. The company reported -€0.286 earnings per share for the quarter, missing the consensus estimate of -€0.16 by -€0.127.
Is Eledon Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Eledon Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Eledon Pharmaceuticals, Inc. pay dividends?
Eledon Pharmaceuticals, Inc. does not currently pay dividends.
What is Eledon Pharmaceuticals, Inc.’s EPS estimate?
Eledon Pharmaceuticals, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Eledon Pharmaceuticals, Inc. have?
Eledon Pharmaceuticals, Inc. has 77,187,820 shares outstanding.
What happened to Eledon Pharmaceuticals, Inc.’s price movement after its last earnings report?
Eledon Pharmaceuticals, Inc. reported an EPS of -€0.286 in its last earnings report, missing expectations of -€0.16. Following the earnings report the stock price went down -0.617%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in DE:2TK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.94 (106.56% Upside)
€6.94 (106.56% Upside)
Blogger Sentiment
Bullish
DE:2TK Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.42%
12-Months-Change
Fundamentals
Return on Equity
-96.80%
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
2TK Stock 12 Month Forecast
Average Price Target
€6.94
▲(106.56% Upside)
Technical Analysis
Tvardi Therapeutics
―
Editas Medicine
―
Annexon Biosciences
―
Design Therapeutics
―
Tevogen Bio Holdings
―
Options Prices
Currently, No data available
---